Menu Search
Equities

Truscreen Group Ltd

TRU:ASX

Truscreen Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.02
  • Today's Change-0.002 / -9.09%
  • Shares traded80.24k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jul 26 2024 04:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Company’s cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.

  • Revenue in NZD (TTM)2.11m
  • Net income in NZD-2.05m
  • Incorporated2013
  • Employees--
  • Location
    Truscreen Group LtdLevel 6Equitable Hse, 57 Symonds StreetAUCKLAND 1010New ZealandNZL
  • Phone+64 61 290917475
  • Websitehttps://truscreen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.